Integra LifeSciences Holdings Corporation $IART Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. trimmed its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 2.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,210,624 shares of the life sciences company’s stock after selling 168,503 shares during the period. Vanguard Group Inc. owned about 0.09% of Integra LifeSciences worth $89,556,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Exchange Traded Concepts LLC lifted its position in Integra LifeSciences by 37.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 50,973 shares of the life sciences company’s stock valued at $633,000 after buying an additional 13,760 shares in the last quarter. SG Americas Securities LLC acquired a new position in Integra LifeSciences during the fourth quarter valued at approximately $4,722,000. Assenagon Asset Management S.A. lifted its position in Integra LifeSciences by 15.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 526,302 shares of the life sciences company’s stock valued at $6,537,000 after buying an additional 71,950 shares in the last quarter. GAMMA Investing LLC lifted its position in Integra LifeSciences by 145.9% during the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after buying an additional 3,742 shares in the last quarter. Finally, Invenomic Capital Management LP lifted its position in Integra LifeSciences by 7.2% during the third quarter. Invenomic Capital Management LP now owns 592,212 shares of the life sciences company’s stock valued at $8,486,000 after buying an additional 39,998 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Trading Up 8.2%

NASDAQ IART opened at $14.90 on Thursday. The company’s fifty day simple moving average is $10.44 and its 200-day simple moving average is $11.67. Integra LifeSciences Holdings Corporation has a 52 week low of $8.70 and a 52 week high of $16.49. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. The stock has a market cap of $1.16 billion, a P/E ratio of -2.31 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The business had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. During the same period in the previous year, the company posted $0.41 earnings per share. The business’s revenue for the quarter was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities research analysts predict that Integra LifeSciences Holdings Corporation will post 2.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on IART. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Friday, March 27th. Truist Financial reduced their price target on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research report on Wednesday, April 15th. Citigroup boosted their target price on shares of Integra LifeSciences from $9.00 to $11.00 and gave the stock a “sell” rating in a research report on Wednesday, May 6th. Argus reissued a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Finally, Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Three research analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Integra LifeSciences presently has an average rating of “Reduce” and an average price target of $12.75.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.